Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus KETOZOLE.
ANCOBON vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category C
Category C
Antifungal
Antifungal